Blocking new protein helps immune system to fight cancer
A protein discovery could lead to a new and highly potent immune-therapeutic drug for the eradication of cancers using natural killer cells.
Australian researchers have discovered a protein found in humans that prevents natural killer (NK) cells from fighting cancer and have found that blocking this protein – with a naturally occurring hormone currently commercially available – turbocharges the immune system to fight off the cancer cells.
The discovery, in pre-clinical models, means this hormone, called Follistatin, may be a new and highly potent immune-therapeutic drug for the eradication of cancers such as melanoma.
The research team led by Dr Fernando Guimaraes, from the University of Queensland’s Diamantina Institute and Professor Nicholas Huntington, from the Monash Biomedicine Discovery Institute, together with researchers from the Walter and Eliza Hall Medical Research Institute, studied NK cells in the immune system as these are crucial in protecting against the triggering of cancer and the spread or metastasising of cancer cells.
One of the key reasons why cancer cells take hold and grow occurs when these NK cells are suppressed and to date, the signals that inhibit NK cells have remained a mystery.
The scientists found that a protein (Activin-A) which is found naturally in both healthy human cells and cancer cells, directly disables the NK cell’s capacity to halt cancer growth. Importantly, they were able to block Activin-A in pre-clinical models, using human and mouse NK cell models, with the hormone Follistatin.
“These findings may open the door to novel immune-therapy drugs which provide a deeper and more durable way to overcome the immune suppression seen in cancer, improving patient outcomes,” said Professor Huntington.
The study was published in the journal Science Signaling,